These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17295573)

  • 1. Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment.
    Peterson TJ; Feldman G; Harley R; Fresco DM; Graves L; Holmes A; Bogdan R; Papakostas GI; Bohn L; Lury RA; Fava M; Segal ZV
    J Consult Clin Psychol; 2007 Feb; 75(1):145-53. PubMed ID: 17295573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
    Petersen T; Harley R; Papakostas GI; Montoya HD; Fava M; Alpert JE
    Psychol Med; 2004 Apr; 34(3):555-61. PubMed ID: 15259840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment approaches to major depressive disorder relapse. Part 1: dose increase.
    Schmidt ME; Fava M; Zhang S; Gonzales J; Raute NJ; Judge R
    Psychother Psychosom; 2002; 71(4):190-4. PubMed ID: 12097783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
    Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
    Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.
    Fava M; Schmidt ME; Zhang S; Gonzales J; Raute NJ; Judge R
    Psychother Psychosom; 2002; 71(4):195-9. PubMed ID: 12097784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Moore J; Jones JM; Foxwell AA; King J
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):991-8. PubMed ID: 26598474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turning darkness into light. A new landmark study on the treatment of adolescent depression. Comments on the TADS study.
    Apter A; Kronenberg S; Brent D
    Eur Child Adolesc Psychiatry; 2005 May; 14(3):113-6. PubMed ID: 15959656
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
    Curry J; Rohde P; Simons A; Silva S; Vitiello B; Kratochvil C; Reinecke M; Feeny N; Wells K; Pathak S; Weller E; Rosenberg D; Kennard B; Robins M; Ginsburg G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1427-39. PubMed ID: 17135988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    Psychol Med; 2015 Nov; 45(15):3191-204. PubMed ID: 26098793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).
    Vitiello B; Rohde P; Silva S; Wells K; Casat C; Waslick B; Simons A; Reinecke M; Weller E; Kratochvil C; Walkup J; Pathak S; Robins M; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1419-26. PubMed ID: 17135987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study.
    Scott K; Lewis CC; Marti CN
    J Am Acad Child Adolesc Psychiatry; 2019 Mar; 58(3):319-328. PubMed ID: 30768414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants.
    O'Reardon JP; Chopra MP; Bergan A; Gallop R; DeRubeis RJ; Crits-Christoph P
    Biol Psychiatry; 2004 May; 55(9):957-9. PubMed ID: 15110741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of relapse in a prospective study of fluoxetine treatment of major depression.
    McGrath PJ; Stewart JW; Quitkin FM; Chen Y; Alpert JE; Nierenberg AA; Fava M; Cheng J; Petkova E
    Am J Psychiatry; 2006 Sep; 163(9):1542-8. PubMed ID: 16946178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression.
    Perlis RH; Iosifescu DV; Alpert J; Nierenberg AA; Rosenbaum JF; Fava M
    Psychosomatics; 2004; 45(3):224-9. PubMed ID: 15123848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
    Yang H; Chuzi S; Sinicropi-Yao L; Johnson D; Chen Y; Clain A; Baer L; McGrath PJ; Stewart JW; Fava M; Papakostas GI
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):145-50. PubMed ID: 19572158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
    Kratochvil C; Emslie G; Silva S; McNulty S; Walkup J; Curry J; Reinecke M; Vitiello B; Rohde P; Feeny N; Casat C; Pathak S; Weller E; May D; Mayes T; Robins M; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1412-8. PubMed ID: 17135986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
    Joliat MJ; Schmidt ME; Fava M; Zhang S; Michelson D; Trapp NJ; Miner CM
    J Clin Psychiatry; 2004 Mar; 65(3):373-8. PubMed ID: 15096077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.